R‐CP CHEMOIMMUNOTHERAPY IN PATIENTS WITH IGM PARAPROTEINAEMIC NEUROPATHY PRODUCES IMPROVEMENTS IN FUNCTIONAL, ELECTROPHYSIOLOGICAL AND SEROLOGICAL OUTCOMES. (June 2017)